Ocrevus approved for primary progressive MS in Scotland
The Scottish Medicines Consortium (SMC) has approved Ocrevus (ocrelizumab) as a treatment for primary progressive MS in Scotland.
SMC has recommended that Ocrevus can be prescribed by the NHS for people with early, inflammatory primary progressive MS. This covers people who:
- have had symptoms of primary progressive MS for less than 15 years and
- are able to walk at least 20 metres, with or without walking aids (up to EDSS 6.5) and
- have evidence of MS inflammatory activity on MRI scans
The MS Trust is delighted that Ocrevus has been approved for primary progressive MS. As the first approved treatment for progressive MS in Scotland, this is a landmark decision. But we know this is just the start. More treatments for progressive MS are still desperately needed, and we will continue to fight to ensure everyone with MS can access the treatments they need.
– David Martin, Chief Executive Officer, MS Trust
Ocrevus was approved as a treatment for primary progressive MS in England last year. Roche is working with the NHS in Wales and Northern Ireland to make Ocrevus available throughout the UK. Ocrevus has also been approved as a treatment for relapsing remitting MS in the UK.
About Ocrevus
Ocrevus is the first treatment to be approved for NHS treatment of primary progressive MS (PPMS). People with this form of MS experience disability more rapidly than those with other types. Clinical trials have shown that Ocrevus can slow the worsening of disability in early, inflammatory PPMS, with the potential to delay the need for a wheelchair by seven years.
Ocrevus is taken as an intravenous infusion (drip). The first dose is given as two separate infusions, two weeks apart. Further doses are given as one infusion every six months. The most common side effects include infusion-related reactions such as headache, rashes, fever and nausea. Other side effects include infections such as coughs, colds, chest infections and herpes virus infections (such as cold sores or shingles).


Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 Feb 2021 - 00:00
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.


Exercise is good for your brain
3 Feb 2021 - 00:00
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.


Covid-19 vaccines and MS: Part two
29 Jan 2021 - 00:00
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.


My search for MS support while studying for a PhD
4 Mar 2021 - 00:00
Laura is studying a PhD in Cancer Genomics and was diagnosed with MS in September 2020 following multiple hospital admissions. Here, Laura talks about how this affected her mental health and what more could be done to support other students going through the same thing.


MS, my mental health and a university degree
4 Mar 2021 - 00:00
Scarlet talks about how she learnt to manage her MS and mental health alongside the stresses of completing a university degree.


Receiving an MS diagnosis during my gender transition
22 Feb 2021 - 00:00
Chris shares his experience of being diagnosed with MS at the same time as starting hormone treatment and a surgical gender transition.

Sign up to our emails
Get the latest news and research sent straight to your inbox. Find out first about the latest developments in MS treatments, plus updates on the work of the MS Trust.